

IN THE CLAIMS

Please amend the claims as follows:

1-42 (Cancelled)

43. (New) A method of administering a metered dry powder combined dose of finely divided dry medication powders, comprising:

providing a relative motion between a nozzle of a dry powder inhaler and a dose bed carrying said combined dose of finely divided dry medication powder intended for delivery by the dry powder inhaler, the combined dose comprises metered quantities of at least two medicaments separately deposited on the dose bed, the relative motion causing the nozzle to pass over the combined dose for a simultaneous or sequential delivery of the medicaments during the course of a single suction of air.

44. (New) The method according to claim 43, further comprising:  
introducing the dose bed into the dry powder inhaler.

45. (New) The method according to claim 43, further comprising:  
delivering the medicaments by the dry powder inhaler (DPI) during the course of a prolonged delivery taking place in 0.01 to 6 s.

46. (New) The method according to claim 43, wherein the at least two medicaments are selected from the following two medicament pairs:

Formoterol and Budesonide;  
Formoterol and Ipratropium;  
Formoterol and Fluticasone;  
Formoterol and Tiotropium;  
Ipratropium and Budesonide; and  
Ipratropium and Salbutamol.

47. (New) A dry powder inhaler comprising:  
a nozzle;  
a dose bed;

a combined dose of finely divided dry powders intended for delivery by the dry powder inhaler, the combined dose comprises metered quantities of at least two substances, separately deposited on the dose bed; and

an arrangement for providing a relative motion between the nozzle and the dose bed, such that the nozzle passes over the combined dose for a simultaneous or sequential delivery of the substances during the course of a single suction of air and the relative motion.

48. (New) The dry powder inhaler according to claim 47, further comprising a mouthpiece connected to the nozzle and adapted for receiving an applied air sucking effort.

49. (New) The dry powder inhaler according to claim 47, wherein the nozzle is initially positioned outside an area of the dose bed onto which the substances are being deposited.

50. (New) The dry powder inhaler according to claim 47, wherein the arrangement is arranged for providing the relative motion once an air stream induced in the nozzle exceeds a threshold flow velocity.

51. (New) The dry powder inhaler according claim 47, wherein the dose bed is sealed with at least one foil and the dry powder inhaler further comprises an arrangement for opening the seal allowing the nozzle access to the dose bed.

52. (New) The dry powder inhaler according to claim 51, wherein the dose bed comprises at least two compartments, the at least two substances are deposited in separate compartments and each compartment is provided with a separate seal to prevent interaction between separately deposited substances.

53. (New) The dry powder inhaler according to claim 47, wherein at least one of the at least two substances is composed of a pure, chemical or biologic agent.

54. (New) The dry powder inhaler according to claim 47, wherein at least one of the at least two substances is presented in form of a dry powder compound consisting of an effective amount of a pure, chemical or biologic agent mixed with suitable excipients.

55. (New) The dry powder inhaler according to claim 47, wherein the dose bed is formed as a blister pack, where the dose bed is designed to accept separate deposits of the substances making up the pre-metered combined dose.

56. (New) The dry powder inhaler according to claim 47, further comprising a biologically acceptable, inert substance deposited between the deposits of the at least two substances to prevent the at least two substances from detrimentally interact after forming of the combined dose.

57. (New) The dry powder inhaler according to claim 47, wherein the at least two medicaments are selected from the following two medicament pairs:

Formoterol and Budesonide;  
Formoterol and Ipratropium;  
Formoterol and Fluticasone;  
Formoterol and Tiotropium;  
Ipratropium and Budesonide; and  
Ipratropium and Salbutamol.